• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

辅助性 T 细胞激活在基于树突状细胞的抗癌免疫治疗中的重要性。

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.

机构信息

Department of Tumor Immunology; Nijmegen Centre for Molecular Life Sciences; Radboud University Nijmegen Medical Centre; Nijmegen, the Netherlands.

出版信息

Oncoimmunology. 2013 Jun 1;2(6):e24440. doi: 10.4161/onci.24440. Epub 2013 May 14.

DOI:10.4161/onci.24440
PMID:23894702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3716737/
Abstract

Dendritic cell-based anticancer immunotherapy is feasible, safe and results in the induction of tumor-specific immune responses, at least in a fraction of vaccinated patients. The concomitant activation of cytotoxic and helper T cells, by loading DCs with peptides or electroporating them with the corresponding mRNAs, may further enhance vaccine-induced antitumor responses.

摘要

基于树突状细胞的抗癌免疫疗法是可行的、安全的，并能诱导肿瘤特异性免疫反应，至少在一部分接种疫苗的患者中如此。通过将肽装入 DC 或用电穿孔将相应的 mRNA 转染 DC，同时激活细胞毒性 T 细胞和辅助性 T 细胞，可能进一步增强疫苗诱导的抗肿瘤反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307a/3716737/cf6a614c8174/onci-2-e24440-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307a/3716737/cf6a614c8174/onci-2-e24440-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/307a/3716737/cf6a614c8174/onci-2-e24440-g1.jpg

相似文献

1
Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy.辅助性 T 细胞激活在基于树突状细胞的抗癌免疫治疗中的重要性。
Oncoimmunology. 2013 Jun 1;2(6):e24440. doi: 10.4161/onci.24440. Epub 2013 May 14.
2
Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.肿瘤相关抗原特异性 CD4+ T 细胞对抗肿瘤免疫治疗中树突状细胞疫苗的要求。
Immunotherapy. 2013 Jun;5(6):565-7. doi: 10.2217/imt.13.45.
3
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.靶向 CD4(+) T-helper 细胞可提高树突状细胞疫苗诱导抗肿瘤免疫应答的能力。
Cancer Res. 2013 Jan 1;73(1):19-29. doi: 10.1158/0008-5472.CAN-12-1127. Epub 2012 Oct 18.
4
Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.接受树突状细胞免疫治疗的乳腺癌Balb/C小鼠淋巴结中树突状细胞和T细胞的表型特征
Immunol Lett. 2016 Sep;177:25-37. doi: 10.1016/j.imlet.2016.07.009. Epub 2016 Jul 14.
5
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.给药途径调节晚期黑色素瘤患者树突状细胞疫苗诱导的抗原特异性 T 细胞的产生。
Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.
6
Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.树突状细胞-肿瘤细胞杂交体增强针对小鼠结肠癌的细胞毒性T淋巴细胞诱导：免疫治疗性树突状细胞疫苗接种抗原加载方法的比较分析
Oncol Rep. 2006 Dec;16(6):1317-24.
7
[Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].辅助性T淋巴细胞和细胞毒性T淋巴细胞表位增强树突状细胞肿瘤疫苗对胃癌的免疫治疗效果
Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Mar;9(2):148-51.
8
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.淋巴内树突状细胞疫苗接种可诱导肿瘤抗原特异性、归巢至皮肤的T淋巴细胞。
Clin Cancer Res. 2006 Oct 1;12(19):5801-8. doi: 10.1158/1078-0432.CCR-05-2421.
9
Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.树突状细胞介导的黑色素瘤特异性细胞毒性 T 细胞诱导过程中自然杀伤细胞的辅助活性。
J Immunother. 2011 Apr;34(3):270-8. doi: 10.1097/CJI.0b013e31820b370b.
10
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.用肽或肿瘤裂解物脉冲的树突状细胞对黑色素瘤患者进行疫苗接种。
Nat Med. 1998 Mar;4(3):328-32. doi: 10.1038/nm0398-328.

引用本文的文献

1
Stemness-related lncRNAs signature as a biologic prognostic model for head and neck squamous cell carcinoma.与干性相关的 lncRNAs 特征作为头颈部鳞状细胞癌的生物学预后模型。
Apoptosis. 2023 Jun;28(5-6):860-880. doi: 10.1007/s10495-023-01832-6. Epub 2023 Mar 30.
2
Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma.作为头颈部鳞状细胞癌预后模型的铜死亡相关长链非编码RNA特征
Apoptosis. 2023 Feb;28(1-2):247-262. doi: 10.1007/s10495-022-01790-5. Epub 2022 Nov 8.
3
A novel Pyroptosis-related long non-coding RNA signature for predicting the prognosis and immune landscape of head and neck squamous cell carcinoma.

本文引用的文献

1
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.靶向 CD4(+) T-helper 细胞可提高树突状细胞疫苗诱导抗肿瘤免疫应答的能力。
Cancer Res. 2013 Jan 1;73(1):19-29. doi: 10.1158/0008-5472.CAN-12-1127. Epub 2012 Oct 18.
2
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.皮肤试验浸润淋巴细胞可早期预测树突状细胞疫苗治疗转移性黑色素瘤的临床结局。
Cancer Res. 2012 Dec 1;72(23):6102-10. doi: 10.1158/0008-5472.CAN-12-2479. Epub 2012 Sep 24.
3
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients.
一种新型与细胞焦亡相关的长链非编码 RNA 标志物用于预测头颈部鳞状细胞癌的预后和免疫图谱。
Cancer Med. 2022 Dec;11(24):5097-5112. doi: 10.1002/cam4.4819. Epub 2022 May 14.
4
A novel pyroptosis-related gene signature to predict outcomes in laryngeal squamous cell carcinoma.一种新的与细胞焦亡相关的基因特征可预测喉鳞状细胞癌的预后。
Aging (Albany NY). 2021 Dec 15;13(24):25960-25979. doi: 10.18632/aging.203783.
5
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.晚期黑色素瘤患者接种肿瘤mRNA转染树突状细胞后的免疫反应及长期临床结局
Oncoimmunology. 2016 Oct 18;5(11):e1232237. doi: 10.1080/2162402X.2016.1232237. eCollection 2016.
6
The Antimetastatic and Antiangiogenesis Effects of Kefir Water on Murine Breast Cancer Cells.开菲尔水对小鼠乳腺癌细胞的抗转移和抗血管生成作用
Integr Cancer Ther. 2016 Dec;15(4):NP53-NP66. doi: 10.1177/1534735416642862. Epub 2016 May 26.
7
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.肿瘤微环境中协同抑制分子表达对树突状细胞疫苗接种的临床意义：一场“走走停停”的博弈
Front Immunol. 2013 Dec 3;4:417. doi: 10.3389/fimmu.2013.00417.
mRNA 电穿孔树突状细胞疫苗接种可诱导 III 期和 IV 期黑色素瘤患者产生强烈的肿瘤抗原特异性 CD4+和 CD8+ T 细胞应答。
Clin Cancer Res. 2012 Oct 1;18(19):5460-70. doi: 10.1158/1078-0432.CCR-11-3368. Epub 2012 Aug 15.
4
Cancer immunotherapy via dendritic cells.通过树突状细胞进行癌症免疫疗法。
Nat Rev Cancer. 2012 Mar 22;12(4):265-77. doi: 10.1038/nrc3258.
5
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.信使核糖核酸电穿孔树突状细胞在黑色素瘤患者淋巴结中对肿瘤抗原的原位表达。
Cancer Res. 2009 Apr 1;69(7):2927-34. doi: 10.1158/0008-5472.CAN-08-3920. Epub 2009 Mar 24.
6
Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.聚肌苷酸-聚胞苷酸可阻止临床级树突状细胞经mRNA电穿孔后有效表达抗原。
Cancer Immunol Immunother. 2009 Jul;58(7):1109-15. doi: 10.1007/s00262-008-0626-y. Epub 2008 Nov 19.
7
Dendritic cell vaccines in melanoma: from promise to proof?黑色素瘤中的树突状细胞疫苗：从希望到验证？
Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Epub 2008 Feb 8.
8
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome.在树突状细胞疫苗接种后的迟发型超敏反应皮肤活检中对肿瘤特异性T细胞进行免疫监测与临床结果相关。
J Clin Oncol. 2005 Aug 20;23(24):5779-87. doi: 10.1200/JCO.2005.06.478.
9
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.癌症免疫与免疫治疗中的肿瘤抗原特异性辅助性T细胞
Cancer Immunol Immunother. 2005 Aug;54(8):721-8. doi: 10.1007/s00262-004-0653-2. Epub 2005 Jan 27.
10
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.针对主要组织相容性复合体II类阴性肿瘤诱导细胞毒性T淋巴细胞的最佳诱导对特定辅助性T细胞的需求。
J Exp Med. 1998 Mar 2;187(5):693-702. doi: 10.1084/jem.187.5.693.